Mylan Inc. April 16 said it has launched the birth control patch Xulane (norelgestromin/ethinyl estradiol transdermal system), the generic version of Janssen Pharmaceuticals Inc.'s Ortho Evra.
The Pittsburgh-based company said it received final approval from the Food and Drug Administration for this product, which it said is the first generic of Ortho Evra.
Ortho Evra had U.S. sales of about $152.9 million for the 12 months ended Dec. 30, 2013, according to IMS Health.
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.